NY-AQARA
Aqara, a leading provider of smart home products, announced the launch of its new Motion Sensor P1, an updated model of the best-selling Aqara Motion Sensor. The sensor is a PIR motion and motion-light sensor that detects motion as well as the ambient light status in the room, and can be used for home security and automation. Built on the previous generation, the P1 model further extends the battery life to a record length of up to 5 years*, thanks to more power-efficient technologies and the improved batteries. The new sensor has been made available on Amazon in the US , Canada , Germany and France , as well as via selective Aqara retailers in North America, Europe, Asia and Oceania**. It is expected to hit Amazon UK in the following weeks.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability and better compatibility, the Motion Sensor P1 adds more flexibility for users including a configurable detection timeout and the adjustable sensitivity level. No longer fixed at a 60-second timeout like the predecessor, the P1 sensor allows users to set the detection timeout between 1 to 200 seconds on the Aqara Home app. It’s also possible to set the sensitivity level to high, medium or low, which refers to the distance from which the sensor will be triggered from, so that false alarms could be reduced. By default which is medium sensitivity, the sensor supports a field of view (FoV) of 170° for up to 2 meters and 150° for up to 7 meters.
The P1 motion sensor are compatible with major smart home ecosystems including HomeKit, Alexa, IFTTT and more. Moreover, the sensor will support Matter - the new connectivity standard for IoT devices - via an OTA update of Aqara hubs after the Matter rollout. The sensor itself also supports OTA updates, which means that new features and fixes now can be added after the release of the product.
Motion sensor has become increasingly popular among smart home users, as it is a natural part of the majority of smart home automations. The combination of an Aqara hub, a Motion Sensor P1 and controller devices like smart wall switches and roller shade drivers can automate many routine tasks, such as turning on the lights, opening the sun shades or controlling the TV. Moreover, with P1’s built-in light sensor, the lights could be controlled more precisely. For example, users could set to turn on the hallway lights only when it’s dark and motion is detected, so that energy consumption is reduced, and the lifespan of lights is increased.
To celebrate the launch, Aqara now offers a 10% discount for the new Motion Sensor P1 on its Amazon brand stores. North American customers will enjoy the offer with the promo code MOTIONUS in the US and Canada , while European customers will enjoy it using the promo code EUMOTIONPI in Germany and France . Both codes will be valid through April 29, 2022.
For more details of the Motion Sensor P1, please visit our website .
* Based on lab test, on the assumption of LED trigger indicator disabled and detection timeout of no less than 30 seconds.
** Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005020/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
